Morgan Stanley Health Sciences A
522 Fifth Avenue Jersey City NJ 07311
Map
Phone: 800-869-6397
| Category: | Health | | Fund Family: | Morgan Stanley | | Net Assets: | 119.24M | | Year-to-Date Return: | 9.85% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 28-Jul-97 |
|
Michael Nolan
Lead Manager since
30-Jun-08 | | | Nolan has been associated with the Investment Adviser in an investment management capacity since November 2005. Prior to November 2005, he was responsible for Morgan Stanley & Company?s collateralized debt obligation business in Europe. |
| Min Initial Investment: | $1,000 | | Min Initial Investment, IRA: | $1,000 | | Min Initial Investment, AIP: | $100 | | Min Subsequent Investment: | $100 | | Min Subsequent Investment, IRA: | $100 | | Min Subsequent Investment, AIP: | $100 |
|
| |
| The investment seeks capital appreciation. The fund normally invests at least 80% of assets in common stocks (including depositary receipts) of health science companies throughout the world. It may invest up to 50% of net assets in foreign securities, including emerging-market securities. The fund may invest the remaining 20% of assets in the common stock of non-health science companies, preferred stock and investment-grade fixed-income securities. |
| Last Dividend
| YFT_NOT_APPLICABLE_ABBREVIATION | | Last Cap Gain
(15-Dec-08):
| 0.45 | | Annual Holdings Turnover
| YFT_NOT_APPLICABLE_ABBREVIATION | | Average for Category:
| 109.30% |
|
| Expense | HCRAX | Category
Avg | | Total Expense Ratio: | 1.50%
| 1.67% | | Max 12b1 Fee: | 0.25%
| N/A | | Max Front End Sales Load: | 5.25%
| 5.35% | | Max Deferred Sales Load: | %
| 2.88% | | 3 Yr Expense Projection*: |
$ 974 | $716 | | 5 Yr Expense Projection*: |
$ 1,300 | $1,069 | | 10 Yr Expense Projection*: |
$ 2,222 | $2,090 |
|
|
0.72% Nasdaq 
Profile
